- Home
- PSNL vs FORA Comparison
PSNL vs FORA Comparison
Compare PSNL & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | FORA |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.8M | 69.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PSNL | FORA |
|---|---|---|
| Price | $7.90 | $2.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $10.71 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 30.1K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,103,000.00 | $28,106,911.00 |
| Revenue This Year | N/A | $47.82 |
| Revenue Next Year | $20.33 | $10.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 37.47 |
| 52 Week Low | $2.83 | $1.64 |
| 52 Week High | $11.40 | $4.03 |
Technical Indicators
Market Signals| Indicator | PSNL | FORA |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 47.17 |
| Support Level | $7.88 | $2.06 |
| Resistance Level | $9.10 | $2.12 |
| Average True Range (ATR) | 0.47 | 0.05 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 12.87 | 53.33 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.